How Pharma Teams Use HCP Data to Find Untapped Commercial Opportunities

Most commercial teams start every planning cycle with a target list they already trust. It carries the high-decile prescribers, the physicians reps already have relationships with, the accounts that closed last year.

The list feels like the market. It is closer to a photograph of the part of the market the team has already found.

That is a very important distinction today because the physicians on those lists are the most contested customers in healthcare. More than half of US physicians place moderate-to-severe restrictions on sales rep access and the doctors who see the most reps are the same high-value prescribers every competitor has already identified.

A target list built from prescribing history and existing relationships points a team at the crowded center of the market and says nothing about the edges, where a competitor has not yet planted a flag.

HCP data for pharma is how teams see those edges. Claims records, procedure and diagnosis codes, affiliation networks, and geographic patterns describe what physicians do in practice and which patients they treat, not only who has already written a script.

Read that way, the same provider data most teams use to manage known relationships becomes a tool for finding the ones they are missing.

Why Established HCP Target Lists Can Hide New Commercial Opportunities

A target list is built backward. It is assembled from signals that already exist like current prescribers of your product, high-decile writers in your class, physicians a rep has met, accounts with a purchase history.

Every one of those signals rewards physicians who are already engaged. None of them surfaces a physician who treats exactly the right patients but has never been called on.

This creates two blind spots. The first is the physician who sees high volumes of the target condition but prescribes little of your class, or prescribes a competitor. Nothing in a prescribing-based list flags them, because they generate no signal in the data the list is built from.

The second is timing. Lists are refreshed on a lag, so a physician who relocated, joined a new group, finished a fellowship, or ramped a procedure over the last two quarters shows up late or not at all.

Then there is the concentration problem as well. Because most teams build lists from the same prescribing and decile data, most teams arrive at similar lists.

The top of every therapeutic area is saturated with reps, samples, and messaging, which is one reason access to those physicians keeps tightening. Working the same contested names harder is a weak substitute for finding physicians the rest of the field has overlooked. Untapped opportunity, almost by definition, sits where the standard list is not looking.

Finding Physicians Outside the Usual High-Value Segments

Decile-based HCP targeting ranks physicians by how much of your product or class they already prescribe. It works well for defending existing share but it can’t find new demand, because it only ranks physicians who already appear in prescribing data for the class.

The more useful question is which physicians treat the right patients regardless of what they currently prescribe. Diagnosis data answers it.

A physician managing a large panel of patients with the target condition is a commercial opportunity whether or not they have ever written your drug, and the size of that patient panel is visible in claims long before it shows up as prescriptions.

Segment on patient volume for the relevant diagnosis instead of on product prescribing, and a different population appears like high-diagnosis, low-prescribing physicians who have the patients but not yet the habit.

Those physicians are the core of any serious commercial opportunity analysis, and they do not all need the same conversation. Some prescribe a competitor, which makes them conversion targets. Others undertreat the condition and need education more than persuasion.

A physician newer to the specialty may simply not have a default therapy yet. HCP segmentation built on clinical activity separates those groups and tells a rep which approach fits, where a list ranked only on current prescribing collapses all of them into one number and misses the difference.

Using Claims and Procedure Data to Reveal Clinical Activity

Prescribing data describes one narrow behavior after it has already happened. Claims data describes the clinical activity underneath it. Procedure codes (CPT and HCPCS) show what a physician does in practice, and diagnosis codes (ICD-10, and broader CCSR categories) show which patients they see. Together they surface physicians and sites that a prescribing-only view never reaches.

The gain is clearest for products tied to a procedure or a diagnostic pathway. A therapy indicated after a specific surgery, or for patients who have had a particular test, has a candidate population defined by procedure volume, not by prescribing.

Finding the highest-volume proceduralists in a market, or the physicians ordering the diagnostic that qualifies a patient for treatment, points reps at demand that exists today and stays invisible in a script-based list. The same approach identifies early adopters of a new technique, who often become the reference physicians a launch depends on.

Used this way, pharma sales intelligence functions as a map of clinical behavior rather than a contact database. When a commercial team can ask which physicians perform a procedure, treat a diagnosis, and at what volume, it can build a target list around the patients being treated instead of the prescriptions already written.

Physician data analytics grounded in claims measures activity as it happens, which is what makes it useful for finding opportunities before competitors have priced them in.

How Physician Affiliations Expose New Commercial Networks

Individual targeting assumes the physician is a free agent. Most are not. As of the start of 2026, roughly 82% of US physicians were employed by hospitals or corporate entities, and a majority of practices are now owned by health systems or corporate groups.

Buying decisions, formulary placement, and even rep access increasingly sit at the level of the organization, not the individual doctor.

Affiliation data turns that structure into a targeting asset. Linking each physician to their health system, group, and sites of care shows the accounts a team is only partially covering, the influential physician you already call on, and the fifteen colleagues in the same network you do not.

It also reframes access. When one system governs formulary and visitation policy across dozens of physicians, the unit of opportunity is the system, and the way in may run through a single account rather than dozens of separate calls.

Beyond direct affiliations, referral patterns show how patients move. They travel along referral paths from primary care and diagnosing specialists to the physicians who treat and prescribe, and those paths are visible in claims.

Referral intelligence shows which upstream physicians feed patients toward your target population, which surfaces a set of providers who shape demand without ever prescribing your product.

For therapies that depend on a diagnosis being made elsewhere before treatment begins, the referring physician is often the untapped opportunity the prescribing list will never name.

Finding Geographic Pockets of Untapped HCP Demand

National target lists average away geography, and geography is where a lot of opportunity hides. Disease prevalence, procedure volume, referral patterns, and treatment norms vary widely by region and metro.

A therapeutic area that looks maturely penetrated at the national level can be badly under-served in specific markets where patient volume is high and product uptake is not.

Pharma market analysis at the regional level finds those pockets. The signal is a gap between clinical demand and current penetration inside a defined geography: a metro with high diagnosis or procedure volume for the target condition, paired with low prescribing of your product or class. That combination marks a territory where the patients exist, the physicians treating them are identifiable, and the commercial coverage is thin.

It is a more precise input to territory design than headcount or historical sales, both of which tend to reinforce wherever the team already spends its time.

Sizing that opportunity requires provider data that can be filtered to a specific area and counted.

Turning HCP Data Into a More Complete Commercial Opportunity Map

No single data type finds untapped opportunity on its own.

Diagnosis data shows patient demand. Procedure and claims data show clinical activity. Prescribing data shows current penetration and competitor share. Affiliation data shows the access path. Geography shows where all of it concentrates.

Opportunity is what appears when these layers are read together, in the space between how many patients need treatment and how much of your product reaches them.

A complete opportunity map resolves that space to named physicians and sites. It takes the population of patients with the target diagnosis, locates the physicians treating them, weights those physicians by procedure and claims volume, subtracts the penetration your prescribing data already accounts for, and attaches each remaining physician to their network and location. What is left is a ranked view of demand you are not yet serving, described precisely enough to act on.

Building this from HCP data analytics rather than from a static list has one practical advantage: it can be re-run. Physicians move, groups get acquired, procedure volumes shift, and a new competitor changes the penetration picture.

A map rebuilt from current claims reflects those changes on the next cycle, where a target list carried forward from last year quietly goes out of date. Pharma commercial intelligence earns its keep when it is treated as a living view of the market instead of a one-time export.

How Alpha Sophia Helps Pharma Teams Discover Untapped HCP Opportunities

Alpha Sophia is a healthcare commercial intelligence platform built on exactly the data this kind of opportunity mapping requires. It covers more than 4 million US providers against a national, all-payor view of medical claims, layered with procedures (CPT/HCPCS), diagnoses (ICD-10 and CCSR), specialty and taxonomy, affiliations and sites of care, prescriptions, open payments, and publication and trial activity.

That combination is what lets a team look past current prescribing to the clinical behavior underneath it.

Target Physicians By Clinical Activity

Teams can find the right HCPs by diagnosis, procedure, and prescribing behavior, ranked by the volume that matters.

This is what surfaces the high-diagnosis, low-prescribing physicians a decile list never flags, along with the high-volume proceduralists tied to a specific therapy or technique.

Size A Pocket Of Demand Before Committing A Territory To It

A team can count an audience or estimate a market for a defined specialty, procedure, or region, so a suspected gap becomes a number before any spend is committed. That turns a sense that a metro is under-covered into a quantified opportunity a team can plan a territory or campaign around.

See The Networks And Influence Behind Individual Physicians

Affiliation data and referral intelligence expose the health systems, groups, and referral paths behind each physician, which reveals whole accounts a team is only partially covering and the upstream providers feeding patients toward its targets.

For influence rather than raw volume, KOL identification surfaces the physicians whose publication and trial activity shapes a therapeutic area.

Match Your Existing List Against The Full Provider Universe

Bulk NPI lookup matches a current target list against a database of more than 4 million US providers, resolving messy names to correct identifiers and showing which physicians the list leaves out. It is the fastest way to measure how much of the real market an existing list actually represents.

Ask Opportunity Questions In Plain Language

Because the platform is agent-native, commercial, marketing, and market access teams can query the data through the in-app assistant or a connection to Claude, ChatGPT, or Cursor over the Model Context Protocol.

A question like which high-volume physicians treat a condition in a given region but rarely prescribe a given class returns a real, current list, grounded in verified claims rather than a model’s guess.

Conclusion

An established target list tells a commercial team who it has already found. It says nothing about who it is missing, and in a market where the best-known physicians are also the most heavily worked, the missing names are often where the growth is.

HCP data changes what a team can see, the physicians treating the right patients without prescribing, the networks behind the individuals, the regions where demand outruns coverage, all described in enough detail to act on.

Working the same list harder means competing for the same saturated physicians. The alternative is to read provider data as a discovery tool and find the demand that list never captured.

FAQs

What is HCP data analytics in pharma?
It is the analysis of healthcare provider data, such as claims, procedures, diagnoses, prescribing, and affiliations, to decide which physicians to target and why. In commercial work it is used to size markets, prioritize physicians, and find demand that basic contact data or prescribing lists miss.

How can pharma companies use HCP data to identify new opportunities?
By segmenting physicians on the patients they treat rather than on what they already prescribe, which surfaces high-diagnosis, low-prescribing physicians a decile list overlooks. Layering diagnosis, procedure, affiliation, and geographic data then locates untapped demand precisely enough to build a territory or campaign around it.

What healthcare data can reveal untapped physician opportunities?
Claims data is the richest source, because procedure codes (CPT/HCPCS) and diagnosis codes (ICD-10) show what physicians do and which patients they see, independent of prescribing. Affiliation and referral data add the networks and patient pathways that point to providers shaping demand without writing scripts.

How can physician affiliations help pharma teams find new opportunities?
With roughly 82% of US physicians now employed by health systems or corporate entities, affiliation data shows the full account behind an individual physician and the colleagues a team is not yet covering. It also reveals referral paths, identifying upstream physicians who feed patients toward a target population without prescribing the product themselves.

How does HCP data improve pharma targeting?
It shifts targeting from existing loyalty to actual clinical activity, so reps prioritize physicians by the patients they treat and the procedures they perform, not only by past prescriptions. That produces target lists aimed at real, current demand and cuts wasted effort on saturated, heavily contested physicians.

How does Alpha Sophia help pharma teams identify commercial opportunities?
Alpha Sophia gives teams a claims-grounded database of 3.9 million-plus US providers, enriched with procedures, diagnoses, affiliations, and prescribing, that can be queried to find, size, and rank untapped physician demand. Its agent-native access lets commercial, marketing, and market access teams ask these questions in plain English and get lists grounded in verified claims rather than a model’s guess.